The Rationale for CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
A panel of experts on multiple myeloma discuss the rationale for CAR T-cell therapy, highlighting BCMA as a target and treatment administration practices.
Now Viewing
EP: 1.The Rationale for CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
EP: 2.The Impact of CAR T-Cell Therapy on Relapsed/Refractory MM Treatment
EP: 3.How CAR T-Cell Therapy Impacts Relapsed/Refractory MM Treatment
EP: 4.Key Takeaways from the CARTITUDE-1 and KarMMa Studies
EP: 5.CAR T-Cell Therapy in R/R MM: Treatment Selection, Safety, and Future Perspectives
EP: 6.Insights from CARTITUDE-4 and KarMMa-3 in R/R MM
EP: 7.Future Perspectives on CAR T-Cell Therapy in Relapsed/Refractory MM
Video content above is prompted by the following questions:
- What is the rationale for using CAR T-cell therapy in patients with relapsed/refractory multiple myeloma?
- What is the target antigen for CAR T-cell therapy in MM and what is its role in the disease?
- How does this process work?
Recent Videos
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
